Analy­sis shows Swiss biotech in­dex out­shines Nas­daq coun­ter­part, but coro­n­avirus chal­lenges are uni­ver­sal

In 2004, the Swiss Stock Ex­change spawned its biotech in­dex — the Swiss Bio+Medtech In­dex (SXI) — as the life sci­ences sec­tor, head­lined by large suc­cess­ful bio­phar­ma com­pa­nies Roche and No­var­tis, took cen­ter stage. In the last five years through Jan­u­ary 2020, SXI has pro­duced re­turns of 59%, out­per­form­ing both the Swiss Per­for­mance In­dex (31%) and the NAS­DAQ Biotech­nol­o­gy In­dex (35%), a new analy­sis shows.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER